Celgene Corporation / Gloucester Pharmaceuticals, Inc.

Cutaneous T-Cell Lymphoma (CTCL)

Disease Overview

Cutaneous T-cell lymphoma is a rare non-Hodgkin lymphoma in which malignant T-cells infiltrate the skin, with mycosis fungoides and Sezary syndrome as the dominant subtypes. It is incurable, follows an indolent-to-aggressive course, and tends to be diagnosed late because early lesions mimic eczema or psoriasis.

Competitive Landscape

By late 2009 the CTCL treatment paradigm relied on skin-directed therapies (topical steroids, nitrogen mustard, phototherapy, total-skin electron beam) for early-stage disease and systemic agents for advanced disease, where options were narrow. Targretin (bexarotene, Eisai), Ontak (denileukin diftitox, Eisai/Ligand), and Zolinza (vorinostat, Merck — the first HDAC inhibitor approved in CTCL, 2006) defined the systemic landscape. Istodax (romidepsin) entered as the second HDAC inhibitor and won FDA approval in November 2009, weeks before the Celgene-Gloucester deal. Celgene paid $340M upfront plus up to $300M in regulatory milestones to acquire Gloucester, betting that romidepsin's expansion into peripheral T-cell lymphoma (PTCL) would unlock a much larger label — a thesis confirmed when Istodax received PTCL approval in June 2011. Industry analysts framed the deal as putting Istodax on a collision course with Allos Therapeutics' newly approved Folotyn (pralatrexate) for PTCL. The deal mattered because it gave Celgene a second oncology asset alongside Revlimid/Vidaza and a beachhead in T-cell lymphoma at a moment when the company was actively diversifying beyond multiple myeloma. Source: https://pharmatimes.com/news/celgene_expands_cancer_portfolio_with_gloucester_pharma_buy_984140/